Research across Plasma cell dyscrasias
Related studies from across the Plasma cell dyscrasias family.
D-dimer elevated in high-risk multiple myeloma with pooled SMD of 1.60
D-dimer levels higher in high-risk multiple myeloma patients
This meta-analysis examined plasma D-dimer levels in patients with multiple myeloma, comparing high-risk groups (advanced ISS stage, venous …
A new analysis finds D-dimer levels are much higher in multiple myeloma patients at high risk for complications. This simple blood test coul…
Mezigdomide plus carfilzomib and dexamethasone improves progression-free survival to 18.0 months in multiple myeloma
Trial shows mezigdomide improves progression-free survival in multiple myeloma
This Phase 3 randomized controlled trial of 479 adult patients with measurable multiple myeloma found that mezigdomide plus carfilzomib and …
A new treatment combination involving mezigdomide and carfilzomib significantly extended the time patients lived without their cancer progre…
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
Daratumumab improves progression-free survival in patients with cytogenetically high-risk multiple myeloma
Daratumumab shows significant progress for high risk multiple myeloma
This meta-analysis evaluated the impact of daratumumab on progression-free survival in patients with cytogenetically high-risk multiple myel…
A new analysis shows that the drug daratumumab significantly slows the progression of high risk multiple myeloma in patients.
D-VRd ranks highest for progression-free survival among anti-CD38 regimens in transplant-ineligible multiple myeloma
New data ranks best treatments for transplant-ineligible multiple myeloma
This network meta-analysis of 6 trials involving 3162 patients evaluated various treatment nodes for transplant-ineligible newly diagnosed m…
A large review of 3,162 patients reveals which combinations of drugs work best to keep multiple myeloma from progressing.
IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma
New Proteins May Help Control Inflammation in Multiple Myeloma Treatment
This mini-review explores the roles of IL-37 and IL-38 as potential immunoregulatory checkpoints in patients with relapsed/refractory multip…
Two specific proteins, IL-37 and IL-38, may help control dangerous inflammation during CAR-T cell therapy for multiple myeloma.
Talquetamab monotherapy linked to 51% any-grade infection rate in relapsed/refractory myeloma
New data shows infection risks for patients on talquetamab
This systematic review and meta-analysis assessed infection risk with talquetamab in relapsed/refractory multiple myeloma. Pooled rates were…
Patients with relapsed or refractory multiple myeloma may face significant infection risks when treated with the drug talquetamab.
Ciltacabtagene autoleucel is associated with higher non-ICANS neurologic toxicity rates than idecabtagene vicleucel
Trial shows specific risks for some patients with multiple myeloma
This meta-analysis of 4,630 patients evaluates non-ICANS neurologic toxicities (NINTs) following BCMA-directed CAR-T therapy in multiple mye…
New data reveals that one type of CAR-T cell therapy carries a higher risk of nerve issues than others for patients with multiple myeloma.
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration
Trial compares continuous versus fixed duration lenalidomide for myeloma
This Phase 3 randomized trial of 516 patients with standard-risk newly diagnosed multiple myeloma found that indefinite-duration lenalidomid…
A large trial found that continuing lenalidomide treatment indefinitely did not improve overall survival compared to a fixed two-year plan.
VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7
Current risk tools for blood clots in multiple myeloma patients do not work well enough for doctors to trust
This systematic review and meta-analysis of 14 studies evaluated VTE risk prediction models in multiple myeloma. Pooled VTE incidence was 7.…
A review of fourteen studies found that existing models fail to accurately predict blood clots in multiple myeloma patients. The tools used …
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Systematic review and meta-analysis of BCMA or GPRC5D bispecific antibodies in relapsed refractory multiple myeloma
New antibodies help some myeloma patients live longer, but infection risks are high
This systematic review and meta-analysis evaluates BCMA- or GPRC5D-directed CD3 bispecific antibodies in 1,900 patients with relapsed or ref…
A review of 1,900 patients found new antibodies helped many with advanced myeloma, yet serious infections and low white blood cell counts re…